Gerresheimer Expands its Pharmaceutical Plastic Operations Into Southern Europe and South America

    Consistent Continuation of Globalisation Path and Extension of Product

    DUSSELDORF, Germany, Dec. 21 /CNW/ - Gerresheimer AG is consistently
continuing its strategy of globalisation and extension of product offerings in
the pharma and life-science sector. With the acquisition of the Spanish
company EDP S.A. it gains a leading manufacturer of pharmaceutical plastic
packaging which contributes to the Group a total of three plants in Southern
Europe and South America. "Regional expansion opens up important new growth
markets for our Plastic Systems Division. At the same time, EDP ideally
complements our existing product portfolio thus offering globally exploitable
synergies," comments Gerresheimer CEO Dr. Axel Herberg. The transaction is
expected to be completed at the end of January 2008.
    As a leading specialist for pharmaceutical primary packaging and
application systems, Gerresheimer has for a considerable time enjoyed a strong
position with glass products like syringe systems and pharmaceutical vials; in
parallel it has expanded its pharmaceutical and medical plastics business, so
far in Europe particularly. The acquisition of the new company specialising in
plastic substantially expands its sphere of activity in this segment.
    EDP with production plants in Spain (Zaragoza and Valencia) and Argentina
(Buenos Aires) concentrates on PET containers for the pharmaceutical industry
and is the market leader in this important field. This company's annual sales
total around EUR32m.
    The products of the EDP company provide an ideal match, which will by no
means be limited to the local markets. Pharma packaging based on PET, as
produced by EDP in Spain and Argentina, represents a real range expansion,
which Gerresheimer can complement with drug delivery systems to provide a
system approach. At the same time, the Spanish and South American markets of
the new subsidiary are opened up for innovative packaging and system
technologies from existing Gerresheimer plants. Gerresheimer's pharmaceutical
plastics business ranks among the market leaders, so far in Europe
    As Herberg stresses, full integration of the new company into the Group
is to be completed in the first half of 2008. The new subsidiary currently
achieves an EBITDA margin of around 17%. Through targeted technical and
financial optimisation measures the EBITDA margin should be increased to well
above 20%.

    About Gerresheimer

    Gerresheimer employs around 10,000 people in 37 locations across Europe,
America and Asia. The Group's product range extends from glass and plastic
medicine bottles to complex drug-delivery systems for the pharma and
life-science industries. The product spectrum includes sterile syringes,
inhalers and other system-based solutions for safer dosage and delivery of
medications. The Group enjoys a leading position in a market which is
characterised by high technical and regulatory barriers and where
Gerresheimer's products must satisfy the strictest quality standards of the
international pharmaceutical supervisory bodies. The Group achieves worldwide
sales of more than EUR950m.

For further information:

For further information: Burkhard Lingenberg, Director Corporate PR &
Marketing, Telephone: +49-211-6181-250, Telefax: +49-211-6181-241, e-mail:; Internet:

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890